108 related articles for article (PubMed ID: 2478794)
1. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Hagemeijer F; Roth W; Brand HJ
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
Baumann G; Ningel K; Permanetter B
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing.
Hagemeijer F; Brand HJ; Roth W
J Cardiovasc Pharmacol; 1989 Aug; 14(2):302-10. PubMed ID: 2476606
[TBL] [Abstract][Full Text] [Related]
4. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
Hauf GF; Grom E; Jähnchen E; Roskamm H
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Chu KM; Shieh SM; Hu OY
Clin Pharmacol Ther; 1995 Jun; 57(6):610-21. PubMed ID: 7781260
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function.
Permanetter B; Sebening H; Hartmann F; Klein G
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S36-40. PubMed ID: 2478790
[TBL] [Abstract][Full Text] [Related]
7. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
[TBL] [Abstract][Full Text] [Related]
8. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.
Pouleur H; Hanet C; Schröder E; Col J; Van Mechelen H; Etienne J; Rousseau MF
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S18-22. PubMed ID: 2478787
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic profile of the cardiotonic agent pimobendan.
van Meel JC; Diederen W
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S1-6. PubMed ID: 2478784
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction.
Remme WJ; Wiesfeld AC; Look MP; Kruyssen HA
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S41-4. PubMed ID: 2478791
[TBL] [Abstract][Full Text] [Related]
11. Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent.
Kitzen JM; Lynch JJ; Driscoll EM; Lucchesi BR
J Pharmacol Exp Ther; 1988 Mar; 244(3):929-39. PubMed ID: 3252039
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular effects of UD-CG 212 CL, a metabolite of pimobendan, in anaesthetized pigs.
Verdouw PD; Levinsky L; Duncker DJ; Rutteman AM; Saxena PR
Eur J Pharmacol; 1987 Jun; 137(2-3):219-26. PubMed ID: 2886352
[TBL] [Abstract][Full Text] [Related]
13. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
[TBL] [Abstract][Full Text] [Related]
14. Calcium sensitization with pimobendan: pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure.
Hagemeijer F
Eur Heart J; 1993 Apr; 14(4):551-66. PubMed ID: 8472722
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo.
von Meel JC
Arzneimittelforschung; 1985; 35(1A):284-8. PubMed ID: 4039168
[TBL] [Abstract][Full Text] [Related]
16. Effects of pimobendan on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside.
Hasenfuss G; Holubarsch C; Heiss HW; Allgeier M; Just H
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S31-5. PubMed ID: 2478789
[TBL] [Abstract][Full Text] [Related]
17. Decrease in Ca(2+)-sensitizing effect of UD-CG 212 Cl, a metabolite of pimobendan, under acidotic condition in canine ventricular myocardium.
Takahashi R; Shimazaki Y; Endoh M
J Pharmacol Exp Ther; 2001 Sep; 298(3):1060-6. PubMed ID: 11504803
[TBL] [Abstract][Full Text] [Related]
18. Effects of pimobendan and its metabolite on myofibrillar calcium responsiveness and ATPase activity in the presence of inorganic phosphate.
van Meel JC; Entzeroth M; Redemann N; Haigh RM
Arzneimittelforschung; 1995 Feb; 45(2):136-41. PubMed ID: 7710434
[TBL] [Abstract][Full Text] [Related]
19. Systemic haemodynamic actions of pimobendan (UD-CG 115 BS) and its O-demethylmetabolite UD-CG 212 Cl in the conscious pig.
Duncker DJ; Hartog JM; Levinsky L; Verdouw PD
Br J Pharmacol; 1987 Jul; 91(3):609-15. PubMed ID: 3607369
[TBL] [Abstract][Full Text] [Related]
20. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Petein M; Levine TB; Cohn JN
Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
